Objectives: Hair plays a significant role in shaping the appearance of an individual. Loss of hair can lead to serious effects on social esteem of an individual. The most common cause of hair loss is Androgenetic Alopecia (AGA).This hereditary disorder followed a specific pattern causing progressive thinning of hair in both Men and Women. There are many therapies prescribed, but each of these therapies come with their own set of pros and cons.
The objective of this paper is to discuss the use of a patented, novel, growth factor formulation in hair growth & to evaluate the evidence available for the same.
Introduction: The aim of the current study is to list and evaluate the evidence for the efficacy of therapy with this patented, novel, growth factor formulation, in the treatment of Male Androgenetic Alopecia, Female Pattern Hair Fall, in Alopecia Areata, in Chemotherapy Induced Hair Fall and in Seborrheic Dermatitis. The objective is also to compare the efficacy when compared with Platelet Rich Plasma (PRP) therapy. Safety and efficacy of this formulation is also evaluated, as are various methods for the administration of the same.
Materials / method: Various published papers on the formulation will be evaluated, as will be evaluated the current data on file, pending publication.
Results: Evidence forms the bedrock of our practice and as such, the current evidence seems to suggest that this patented, novel, growth factor formulation is a very promising and exciting non-surgical addition to the global hair growth scenario.
Conclusion: Data and the published evidence suggests that this patented, novel, hair growth factor formulation works really well in various types of hair loss and alopecia. The evidence shows a far greater efficacy than PRP therapy, in comparison.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。